This study is for patients who have been diagnosed with stage 2 or stage 3 breast cancer and their doctor has recommended that they receive radiation therapy after mastectomy to prevent your breast cancer from coming back. The purpose of this study is to determine whether a short-course radiation therapy option (3 to 4 weeks) after mastectomy is as safe and effective in the setting of breast reconstruction as the usual 5 to 6 week treatment course.
This study looks at the risks and benefits of the "usual approach" (a combination of surgery, radiation and/or hormonal therapy) compared to the close monitoring approach (meaning the condition is watched with follow-up exams and tests such as mammograms, breast ultrasounds, and breast MRI). This study is being conducted because researchers wish to know whether, after 2 years, clinical and quality of life outcomes for women with low risk DCIS who receive usual treatment are the same as those for women with low risk DCIS who receive close monitoring.
The overall goal of this study is to see if taking BosPure (boswellia serrata) will change the make up of the tumors of patients who have breast and colon cancer. BosPure is a supplement made from the boswellia serrata plant, which helps to reduce inflammation in the body. BosPure is not approved by the United State Food and Drug Administration (FDA) for the treatment of your disease.
The purpose of this study is to identify safe pharmaceutical agents that can reduce the AGE levels in subjects with advanced cancer. The term "AGE" (advanced glycation endpoints) refers to sugar-derived metabolites that are linked to lifestyle choices and can contribute to cancer.
Some drugs used to treat cancer raise a patient's risk of febrile neutropenia. Febrile neutropenia is a condition that involves a fever and a low number of neutrophils (a type of white blood cell) in the blood. Having a low number of neutrophils puts a patient at risk of infection. Colony-stimulating factors (CSFs) are medications sometimes given to patients getting cancer treatment to prevent or treat febrile neutropenia. CSFs are given as an injection under the skin or into a vein.
Current guidelines say that doctors should give CSF during cancer treatment based on how likely it is that the drugs will raise the risk of febrile neutropenia. Research shows that many doctors do not follow these guidelines. This may be harming patients. Underuse of CSFs can raise a patient's risk for febrile neutropenia. Overuse or unneeded use of CSFs can lead to side effects, like bone and muscle pain, but give no benefit and can be costly to the patient.
In some clinics there is an automated system that helps doctors decide when to use CSFs. The system prescribes CSFs when there is a high risk that the drugs will cause febrile neutropenia. It does not prescribe CSFs when there is a low risk that the drugs will cause febrile neutropenia. The research study team wants to find out if this type of system can help doctors use CSF when it is needed and not use it when it is not needed. The study team also wants to learn about the benefits and risks of using CSF with cancer treatment drugs that have a moderate (not high and not low) risk of febrile neutropenia.
The purpose of this study is to find out if the drug ribociclib (LEE011), when taken with standard treatment, everolimus (Afinitor®) and exemestane (Aromasin®), is safe and beneficial in men and postmenopausal women who have advanced breast cancer that has recently become resistant to anti-estrogen therapy (meaning that your tumor progressed while on or being recently treated with anti-estrogen treatment). Participants in this study will remain on this study until his/her disease gets worse, or he/she no longer wish to participate.
The purpose of this study is to test study treatments that combine an investigational drug (ONT-380) with two approved drugs (capecitabine and trastuzumab) in subjects with advanced breast cancer to find out what effects, good or bad, it may have on you and your disease.
This research study is for patients who have completed all scheduled surgery, chemotherapy and/or radiation therapy for their cancer within the last 6-12 months and are currently having some type of sleep disturbance. While there is no standard treatment for sleep disturbance for cancer survivors, people who do not take part in this study may take over-the-counter or prescription medications, receive cognitive behavioral therapy, or exercise as a means of attempting to manage their sleep problems.
Sleep disturbance, particularly insomnia, is a common problem for cancer survivors. Insomnia can be described as excessive daytime napping, difficulty falling asleep, difficulty staying asleep, or waking up earlier than you would like. Insomnia can increase fatigue, impair physical function, impair immune function, cause circadian rhythms (known as your biological clock) to be disrupted and decrease quality of life.
Because there is no ideal standard of care for effectively treating sleep problems in cancer survivors, the purpose of this study is to compare the effectiveness of three different treatments for improving sleep problems and determine which is best. The three treatments are yoga, survivorship health education, and cognitive behavioral therapy (CBT-I).
Study participation will be approximately 8 months.
The primary objective of this study is to assess the rate of appropriate referral of newly diagnosed breast cancer patients at increased risk for HBOC to genetic counseling in the community oncology setting among patients at clusters receiving the active intervention compared with patients at clusters receiving the passive intervention. Participating centers without in-house genetic counseling services will be randomized to receive either an active or passive provider education/information intervention regarding identification and referral of breast cancer patients at risk for hereditary breast and ovarian cancer (HBOC) to genetic counseling services. Practice patterns and patient outcomes will be compared between the two intervention groups. No data from specific sites will be released; only group comparisons (i.e., between the two intervention groups) will be made. Registered patients will receive Patient Questionnaire approximately 12 months after registration.
This study is for females, ages 25-55, who have tested positive for atypia (early cell changes that are thought to be a marker of breast cancer risk) in the breast, and are considered high risk for the development of breast cancer in the future.
The purpose of this research study is to test whether metformin, a drug commonly used to treat diabetes, is able to get rid of atypia (marker of breast cancer risk) in women at increased risk for breast cancer. This study will test for the presence of atypia in the breast after metformin is given to see if it can get rid of atypia. The study sponsor would like to compare the effects, good and/or bad, of metformin or placebo on atypia to find out which is better. In this study, patients will get either metformin or a placebo (an inactive product) for the first twelve months. After the first twelve months, women who received placebo during the first twelve months can choose to receive metformin for the second year.
Note: The standard drug used for the "breast cancer prevention" is tamoxifen. If you are eligible to take tamoxifen, you must be offered tamoxifen prevention as part of your clinical care and you must have refused tamoxifen treatment to be on this study. Metformin and tamoxifen are not similar and function differently. This study is not investigating the use of tamoxifen.
While on this research study patients will have the Random Periareolar Fine Needle Aspiration (RPFNA) of their breasts to test for atypia (marker of breast cancer risk), before the study starts, and also at 12 and 24 months (24 month optional for placebo-only group for patients who remain on placebo arm and will not receive metformin) after the study starts. If the pathologist does not identify atypia in the samples you will not be able to participate. You will also provide blood during this study to determine if changes in your blood are related to changes in your breasts. You will need to provide a little less than 4 tablespoons of blood for this research study.
Study participation will last for 48 months (2 years).